Novocure, a solid tumor treatment company, has seen promising results in a phase III trial with it’s NovoTTF therapy. NovoTTF therapy is indicated for chemotherapy free treatment of recurrent glioblastoma multiforme (GBM) brain tumors. The results of the trial were comparable to active chemotherapy in extending overall survival, with minimal side effects and far better quality of life. Read the news release to find out more about NovoTTF-100 that is currently approved for marketing in the US and Europe.
About UsOMEDtech, provides quality system design, regulatory, compliance, clinical and operations consulting services that are focused on helping managers and companies meet the aggressive challenges of bringing new medical device products to market.
Follow Us on Twitter
Like Us on Facebook